Systemic treatments for resectable carcinoma of the esophagus
Issued Date
2023-01-01
Resource Type
ISSN
10079327
eISSN
22192840
Scopus ID
2-s2.0-85168936913
Journal Title
World Journal of Gastroenterology
Volume
29
Issue
30
Start Page
4628
End Page
4641
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Gastroenterology Vol.29 No.30 (2023) , 4628-4641
Suggested Citation
Leowattana W., Leowattana P., Leowattana T. Systemic treatments for resectable carcinoma of the esophagus. World Journal of Gastroenterology Vol.29 No.30 (2023) , 4628-4641. 4641. doi:10.3748/wjg.v29.i30.4628 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/89387
Title
Systemic treatments for resectable carcinoma of the esophagus
Author(s)
Other Contributor(s)
Abstract
One of the most prevalent malignancies in the world is esophageal cancer (EC). The 5-year survival rate of EC remains pitiful despite treatment advancements. Neoadjuvant chemoradiotherapy in conjunction with esophagectomy is the standard of care for patients with resectable disease. The pathological complete response rate, however, is not acceptable. A distant metastasis or a locoregional recurrence will occur in about half of the patients. To increase the clinical effectiveness of therapy, it is consequently vital to investigate cutting-edge and potent therapeutic modalities. The approach to the management of resectable EC using immunotherapy has been considerably altered by immune checkpoint inhibitors. Systemic immunotherapy has recently been shown to have the potential to increase the survival of patients with resectable EC, according to growing clinical data. A combination of chemotherapy, radiation, and immunotherapy may have a synergistic antitumor impact because, according to mounting evidence, these treatments can stimulate the immune system via a number of different pathways. In light of this, it makes sense to consider the value of neoadjuvant immunotherapy for patients with surgically treatable EC. In this review, we clarify the rationale for neoadjuvant immunotherapy in resectable EC patients, recap the clinical outcomes of these approaches, go through the upcoming and ongoing investigations, and emphasize the difficulties and unmet research requirements.
